Palbociclib was the first CDK4/6 inhibitor to be FDA approved in 2015 for the treatment of postmenopausal women with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer [69]. Here, ERBB2 is linked to breast carcinoma.